Turn Your Drug’s Patent Clock Into a Revenue Multiplier: Lifecycle Management and the 505(b)(2) Pathway
The Hatch-Waxman Act was never designed to be a gift to branded pharmaceutical companies. Congress passed the Drug Price Competition […]
Buy Old Science Cheap, Sell Proven Biology Expensive
This is the arbitrage opportunity. The pharmaceutical secondary market — distressed assets, out-licensed compounds, abandoned pipelines, post-patent small molecules —
Buy Old Science Cheap, Sell Proven Biology Expensive Read Post »
Sell the Bridge, Not the Gap: How to Turn Expiring Patents into Multi-Billion Dollar Reformulations
The instinct, when a primary patent approaches expiration, is to treat it as a loss event. Revenue projections get marked
Turn Abandoned Patents Into Profit
The pharmaceutical industry operates on a high-risk model where the cost of a single drug approval ranges from $1 billion
Turn Abandoned Patents Into Profit Read Post »
Drug Reformulation Strategy: Buy Seven Years of Exclusivity for $20 Million
Pharmaceutical manufacturers face a revenue contraction of 62% from their top-selling assets by 2030.1 Blockbuster drugs representing $236 billion in
Drug Reformulation Strategy: Buy Seven Years of Exclusivity for $20 Million Read Post »
Sell Before the Cliff Drops: A BD Playbook for Biopharma Equipment Suppliers
How to use market automation and drug patent intelligence to build pipeline before generic entry kills your best customers’ budgets
Sell Before the Cliff Drops: A BD Playbook for Biopharma Equipment Suppliers Read Post »
Forecasting Generic Entry: Combining FDA Orange Book with Paragraph IV Notice Letters
Pharmaceutical companies lose between $200 billion and $400 billion in annual revenue to patent expirations between 2025 and 2030. This
Forecasting Generic Entry: Combining FDA Orange Book with Paragraph IV Notice Letters Read Post »
Win the Patent Fight: Hatch-Waxman Litigation Strategies for Brand and Generic Manufacturers
The Statute That Rewired the Drug Industry In September 1984, President Reagan signed two pieces of legislation that had been
Why Branded Generics Dominate the Pharmaceutical Landscape in Emerging Markets
Branded Generics: The $400 Billion Business That Big Pharma Can’t Ignore In the summer of 2022, a pharmacist in Lagos
Why Branded Generics Dominate the Pharmaceutical Landscape in Emerging Markets Read Post »
